Laihui Luo

5PUBLICATIONS
3CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Apr 25, 2025
The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

Wei Deng, Jin Xie, Tao Wang

|Jul 09, 2024
Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.

Yongqiang Xiao, Wanqing Chen, Wei Deng

|May 14, 2024
Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.

Yongqiang Xiao, Wei Deng, Laihui Luo

|Nov 15, 2023
Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.

Yongqiang Xiao, Guoqing Zhu, Jin Xie

|Dec 29, 2022
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?

Laihui Luo, Yongzhu He, Guoqing Zhu

Pageof 1

Frequent Collaborators

4 joint publications

Yongqiang Xiao

3 joint publications

Wei Deng

2 joint publications

Renfeng Shan